PCSK9 inhibitors: A new era of lipid lowering therapy

doi:10.4330/wjc.v9.i2.76

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (19175)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

1490

WORD

452

HTML

14389

Figures (1-1)

193

Tables (1-2)

226

Sum=16750

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1183

Download

1242

Sum=2425

Feb 26, 2017 (publication date) through Jul 17, 2024

Times Cited of This Article

Times Cited (202)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Cardiol. Feb 26, 2017; 9(2): 76-91
Published online Feb 26, 2017. doi: 10.4330/wjc.v9.i2.76

Open in New Tab Full Size Figure Download Figure

Figure 1 Mechanism and role of PCK9 in low-density lipoprotein-cholesterol metabolism. LDL: Low-density lipoprotein.

Citation: Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: A new era of lipid lowering therapy. World J Cardiol 2017; 9(2): 76-91
URL: https://www.wjgnet.com/1949-8462/full/v9/i2/76.htm
DOI: https://dx.doi.org/10.4330/wjc.v9.i2.76